Forgot your username? Forgot your password? Create an account
BioMedReports.com
Home | About Us | Contact Us
  • Increase font size
  • Default font size
  • Decrease font size
  • FDA Calendar
    • FDA Calendar
    • How To Use The FDA Calendar To Invest
    • Key Tips On Using The FDA Calendar
  • Articles
    • Featured Content
    • FDA News and Approvals
    • Most Popular
    • Latest News
    • Breaking News
    • User Submitted Articles
    • Contribute an Article
    • GlobeNewswire
  • News and Analysis
  • About Us
  • Support
    • Help Desk

Sector News

  • FDA Approves Genentech’s Cotellic™ in Combination With Zelboraf®; FORUM Announces Removal of Partial Clinical Hold on Phase 3 Encenicline Program
    FDA Approves Genentech’s Cotellic™ in Combination With Zelboraf®; FORUM Announces Removal of Partial Clinical Hold on Phase 3 Encenicline Program Below is a look at some of the headlines for companies that made news in the healthcare sector on November 11, 2015.     
    » Read More
  • MediciNova Receives Notice of Allowance for New Patent Covering MN-221; FDA Grants TEVA Therapy Designation for SD-809
    MediciNova Receives Notice of Allowance for New Patent Covering MN-221; FDA Grants TEVA Therapy Designation for SD-809 Below is a look at some of the headlines for companies that made news in the healthcare sector on November 10, 2015.     
    » Read More
  • Capricor Presents Positive Data from the DYNAMIC Clinical Trial; Collegium Announces FDA Tentative Approval for Xtampza(TM) ER
    Capricor Presents Positive Data from the DYNAMIC Clinical Trial; Collegium Announces FDA Tentative Approval for Xtampza(TM) ER Below is a look at some of the headlines for companies that made news in the healthcare sector on November 9, 2015.      
    » Read More
More News


BioMedReports.com

More Articles...
  • Biotech firm prepares for real-life killer bugs
  • MediciNova Receives Notice of Allowance for New Patent Covering MN-221; FDA Grants TEVA Therapy Designation for SD-809
  • Active Stocks: Genetic Technologies & Express Scripts Jump, Warner Chilcott & EXACT Sciences fall
  • The New Drug Application is Actually Supported With 2 Fundamental Phase Three Experimental Trials
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 876

Newsletter

Home | Privacy Policy
© 2021 BioMedReports.com. All rights reserved
powered by: MarketMediaConnect Inc